Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;205(5):2077-2079.
doi: 10.1111/bjh.19772. Epub 2024 Sep 14.

Teclistamab for relapsed refractory multiple myeloma patients on dialysis

P Lebreton  1 , F Lachenal  2 , S Bouillie  3 , G M Pica  4 , H Aftisse  5 , L Pascal  6 , L Montes  7 , M Macro  8 , N Johnson  9 , S Harel  10 , M Fernandez  11 , B De Renzis  12 , B Lioure  13 , A Lazareth  14 , M Javelot  3 , C Louni  15 , A Huart  16 , A Perrot  17
Affiliations

Teclistamab for relapsed refractory multiple myeloma patients on dialysis

P Lebreton et al. Br J Haematol. 2024 Nov.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Dimopoulos MA, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison SJ, et al. Management of multiple myeloma‐related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol. 2023;24:e293–e311.
    1. Jian Y, Zhou H, Xie W, Ren Y, Zhang Z, Yang G, et al. Impact of dialysis dependence on survival for multiple myeloma with renal impairment: a multicenter study in China. Am J Cancer Res. 2023;13(4):1571–1581.
    1. Moreau P, Garfall AL, van de Donk N, Nahi H, San‐Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505.
    1. Joiner L, Bal S, Godby KN, Costa LJ. Teclistamab in patients with multiple myeloma and impaired renal function. Am J Hematol. 2023;98:E322–E324.

LinkOut - more resources